To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of melanoma with high risk of recurrence.
 
Status In progress
Process STA
ID number 1266

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 April 2018 Invitation to participate
02 October 2017 - 31 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
28 September 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance